评估在常规HIV检测中利用新型cobas HIV-1/HIV-2定性核酸检测的經濟后果
当前美国CDC三步算法与使用cobas HIV-1/HIV-2定性核酸检测的替代算法相比,替代算法每例患者增加8.95美元成本,但总检测数减少21.29%,重复检测数从20.7降至4.5。作者认为替代算法可简化HIV检测流程且不显著增加医疗成本。
要点
- 替代算法每例患者增加8.95美元成本,但总检测数减少21.29%。
- 当前算法重复检测20.7次,替代算法重复检测4.5次。
- 作者认为替代算法可简化HIV检测且对支付方成本中性。
核心结论
- 使用cobas HIV-1/HIV-2定性核酸检测的替代算法显著减少准确诊断HIV所需的累积检测数,同时对支付方保持成本中性,并可减少不良患者结局。
研究设计与样本
- 估计2.44%的人接受抗原-抗体免疫测定检测,其中0.72%为反应性。
- 基于真实世界证据,估计Geenius和cobas检测后因不确定/无效结果而重复检测的比例分别为8.78%和1.95%。
- 应用HIV-1/HIV-2患病率、检测性能和重复检测率估算总检测数和每种算法的总成本。
主要发现
- 在175例患者中,当前算法和替代算法的总体支付方成本分别为5299.37美元和6870.24美元,每例患者增加8.95美元成本。
- 使用替代算法时总检测数减少21.29%(191.8 vs 243.7)。
- 当前算法和替代算法的总重复检测数分别为20.7和4.5。
临床怎么用
- 作者认为所提出的替代算法可简化HIV检测而不显著增加医疗成本,并减少不良患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficient and cost-effective testing strategies are needed to reduce human immunodeficiency virus (HIV) transmission. The aim of the current study was to compare the costs of using the current Centers for Disease Control and Prevention 3-step HIV algorithm-antigen-antibody screening, differentiation immunoassay (Geenius), and nucleic acid amplification test against an alternative algorithm using a cobas HIV-1/HIV-2 qualitative nucleic acid amplification test. METHODS: A 1-year cost calculator was developed from a US payer perspective using a decision-tree approach to simulate testing in a population of 1 million individuals. An estimated 2.44% of individuals were tested for HIV with an antigen-antibody immunoassay test, of which 0.72% were reactive. Based on real-world evidence, it was estimated that 8.78% and 1.95% of those tested with Geenius and cobas, respectively, were retested after indeterminate/invalid results. HIV-1/HIV-2 prevalence was applied along with test performance and retest rates to estimate the total number of tests required and the overall costs per algorithm. RESULTS: Among 175 patients, overall payer costs with the current and alternative algorithm were $5299.37 and $6870.24, respectively, yielding $8.95 additional cost per patient. The total number of tests performed decreased by 21.29% using the alternative algorithm (191.8 vs 243.7). The total number of retests were 20.7 and 4.5 with the current and alternative algorithm, respectively. CONCLUSIONS: The study demonstrates a significant reduction in the number of cumulative tests needed to diagnose HIV accurately while remaining cost neutral to payers using the alternative algorithm. These findings suggest that the proposed alternative algorithm can streamline HIV testing without a substantial increase in healthcare costs and minimize adverse patient outcomes.
引用
- Bilir SP, Krishnamurthy P, Karichu JK, et al. Estimating the Economic Consequences of Leveraging the Novel cobas HIV-1/HIV-2 Qualitative Nucleic Acid Amplification Test in Routine HIV Testing. Clin Infect Dis. 2025. PMID: 39879555. doi:10.1093/cid/ciaf025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。